Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)

Starting soon · Phase 2

Conditions studied: Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic, Papillary Thyroid Carcinoma

In brief

This is an open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of Sacituzumab Tirumotecan (sac-TMT) monotherapy in patients with recurrent or metastatic adenoid cystic carcinoma (ACC) of salivary gland origin and papillary thyroid carcinoma (PTC). A total of 68 patients will be enrolled over in 18-month period, with 34 patients in Cohort A (ACC) and 34 in Cohort B (PTC). All participants will receive sac-TMT at a dose of 4 mg/kg administered intravenously on Days 1 and 15 of each 28-day cycle. The primary endpoint is the objective response rate (ORR), defined as the proportion of patients achieving a complete or partial response as assessed by the site investigators. Secondary endpoints include progression-free survival, overall survival, disease control rate, safety and tolerability, dose intensity, and relative dose intensity.

Key facts

Study ID

NCT07521670

Run by

National Cancer Centre, Singapore

People needed

68

Starts

2026-11-01

Expected to finish

2028-10-31

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Common Eligibility Criteria for Cohorts A and B
• Unresectable locally advanced or recurrent/metastatic adenoid cystic carcinoma or papillary thyroid carcinoma.
• Trophoblast cell-surface antigen 2 (TROP2) expression testing by immunohistochemistry or other methods is not required for enrollment. Provision of archival tumour tissue (where available) will be requested to support retrospective analysis. Waiver for tissue submission may be granted by the Steering Committee on a case-by-case basis if archival tissue is unavailable or insufficient for analysis.
• Age ≥18 years at the time of enrollment (≥21 years in Singapore)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• At least one target lesion *identified on contrast-enhanced CT (head, neck, chest, abdomen, pelvis with ≤5 mm slice thickness) performed within 14 days prior to enrollment (same day of the week within 14 days is acceptable; this applies similarly to other time-based criteria below).
• A non-lymph node lesion with a longest diameter of ≥10 mm or a lymph node lesion with a short axis of ≥15 mm
• No prior treatment with Trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates or antibody-drug conjugates containing anti-topoisomerase I agents.
• Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or pre-treatment baseline level (except for alopecia and vitiligo). Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible.
• No administration of anticancer therapies (e.g., chemotherapy, targeted therapy, immunotherapy) within 13 days prior to enrollment.
• No major surgery under general anesthesia within 27 days prior to enrollment.
• No radiotherapy (including Gamma Knife or CyberKnife) within 13 days prior to enrollment. Thirteen days or fewer of palliative radiotherapy for non-CNS disease prior to enrollment is permitted. The last radiotherapy treatment must have been performed at least 7 days before enrollment.Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.
• Laboratory values within the following criteria based on testing within 14 days prior to enrollment.
• Neutrophil count≥1,500/mm3
• Platelet count≥10x10\^4/mm3
• Hemoglobin≥9.0 g/dL
• AST<100 U/L
• ALT<100 U/L
• Total bilirubin<1.5 mg/dL
• Creatinine<1.5 mg/dL, if >1.5 mg/dL, estimated creatinine clearance ≥30 ml/min. If an estimated value is used, it should be calculated using the Cockcroft-Gault formula.
• Peripheral oxygen saturation (SpO₂) ≥92% on room air within 14 days prior to enrollment.
• For male patients: Must agree to use acceptable contraception (refer to Notes 1,2,3) and refrain from sperm donation for at least 120 days after the last dose of study drug.
• For female patients: Must not be pregnant or breastfeeding and must meet one of the following conditions:
• Not of childbearing potential; or
• If of childbearing potential:

You may not qualify if…

• Active central nervous system (CNS) metastases - including brain metastases, carcinomatous (leptomeningeal) meningitis, or symptomatic spinal metastases that require radiotherapy or surgical intervention. However, patients with previously treated brain metastases may be enrolled if imaging performed at screening shows radiographic stability for at least 28 days with no evidence of progression, they are clinically stable, and they have not required steroid therapy for at least 14 days before enrollment.
• Clinically significant pericardial effusion, pleural effusion, or ascites requiring treatment.
• Has a current and past history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to >480 ms, prior treatment history with cardiotoxic agents and/or other serious cardiovascular and cerebrovascular diseases within 6 months before enrollment.
• Received a live or live-attenuated vaccine within 30 days before enrollment. Administration of inactivated vaccines are allowed.
• Is currently receiving a strong inducer/inhibitor of CYP3A4 that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks.
• Note: A list of strong inducers/inhibitors of CYP3A4 can be found at the following website: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Please note that this list is not exhaustive and that investigators should review the locally-approved label for all concomitant therapy to ensure it is not a strong inducer/inhibitor of CYP3A4.
• Is currently participating in another therapeutic clinical trial. Concurrent enrollment on another therapeutic clinical trial or any trial designed to impact the efficacy of anti-cancer therapy is prohibited.
• Has received an investigational agent or has used an investigational device within 28 days before enrollment.
• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
• Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding carcinoma in situ of the bladder) who have undergone potentially curative resection are not excluded.
• Note: Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA <10 ng/mL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.
• Has an active infection requiring systemic therapy except those permitted in the exclusion criteria 15), 16), and 17) (e.g., HIV, HBV, HCV)
• Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the individual's ability to cooperate with the requirements of the study, or interfere with the individual's participation for the full duration of the study, such that it is not in the best interest of the individual to participate, in the opinion of the treating investigator.
• Severe hypersensitivity (Grades ≥3) to study intervention, any of their excipients, and/or to another biologic therapy.
• Has had major surgery or significant traumatic injury within 27 days before enrollment. Anticipation of the need for major surgery during the course of treatment with study intervention is also exclusionary.
• Note: Participants who underwent major surgery must have adequately recovered from toxicity and/or complications from the surgery before starting study intervention.
• Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• Participants with HIV infection will be excluded unless all of the following conditions are met:
• Having a CD4+ T-cell count ≥350 cells/mm3 at the time of screening
• Having achieved and maintained virologic suppression, defined as confirmed HIV RNA level below 50 or the LLOQ using the locally available assay, at the time of screening and for at least 12 weeks before screening
• Absence of any AIDS-defining opportunistic infections within the past 12 months
• Being on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before registration and agreeing to continue ART throughout the study Note: The ART regimen must not contain any antiretroviral medications that are strong CYP3A4 inducers/inhibitors/substrates. Refer to https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Please note that this list is not exhaustive and that investigators should review the locally-approved label for all concomitant therapy to ensure it is not a strong inducer/inhibitor/substrate of CYP3A4.
• Positive for HCV RNA, or, if HCV RNA is negative, has not completed curative antiviral therapy at least 28 days prior to enrollment. HCV RNA testing is required only for patients who test positive for HCV antibodies or as mandated by local regulations.
• Positive for HBs antigen, or negative for HBs antigen but positive for either HBs antibody or HBc antibody and positive for HBV DNA quantification. Patients are eligible if HBV DNA is below the lower limit of quantification; however, they will be excluded if they have not received at least 4 weeks of antiviral therapy prior to enrollment.

Where it is running

• National Cancer Center Hospital — Tokyo, Japan
• Sarawak General Hospital — Kuching, Sarawak, Malaysia
• University of Malaya Medical Center — Kuala Lumpur, Malaysia
• National Cancer Centre Singapore — Singapore, Singapore
• Tan Tock Seng Hospital — Singapore, Singapore
• National Cancer Center Korea — Gyeonggi-do, South Korea
• Seoul National University Hospital — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.